Why the study?
The impact of medical weight management on major adverse cardiovascular events compared to metabolic and bariatric surgery and usual care was not established.
Does medical weight management (lifestyle modification with or without obesity medications) reduce the risk of six-component major adverse cardiovascular events compared to metabolic and bariatric surgery or usual care in adults with BMI ≥35 kg/m² and type 2 diabetes?
Does medical weight management (lifestyle modification with or without obesity medications) reduce the risk of six-component major adverse cardiovascular events compared to metabolic and bariatric surgery or usual care in adults with BMI ≥35 kg/m² and type 2 diabetes?
Answers are grounded in this paper and cite their sources.
In adults with class 2 or 3 obesity and type 2 diabetes prior to the availability of semaglutide and tirzepatide, medical weight management with older anti-obesity medications did not significantly reduce MACE risk compared to usual care, whereas metabolic and bariatric surgery showed a trend toward lower MACE risk and significantly lower MACE among those achieving ≥15% weight loss.
OBJECTIVE: We assessed the impact of medical weight management (MWM; lifestyle modification ± obesity medications) on major adverse cardiovascular events (MACE) compared to metabolic and bariatric surgery (MBS) and usual care (UC). METHODS: We retrospectively analyzed electronic health records of adults with body mass index (BMI) ≥35 kg/m² and type 2 diabetes mellitus (T2D) at an academic health center from 2010 to 2021. The MWM group was propensity score matched on common confounders 1:1 (versus MBS) and 1:5 (versus UC). The primary outcome was a six-component MACE (all-cause mortality, coronary artery events, cerebrovascular events, heart failure, atrial fibrillation, and nephropathy). Results: Among 2,100 patients (300 MWM, 300 MBS, and 1,500 UC), baseline characteristics were similar among groups. During a median 3.2-year follow-up (range 0-11), the adjusted hazard ratio (aHR) for MACE for MWM versus MBS was 1.61 (0.98-2.65, p=0.06); for MBS versus UC, aHR 0.66 (0.43-1.02, p=0.06); and there was no difference in MWM versus UC, aHR 1.07 (0.77-1.49, p=0.68). CONCLUSIONS: No statistically significant differences in MACE risk were found between those receiving MWM versus UC; there was a trend towards fewer MACE events in those receiving MBS. These findings must be validated in future studies, given that more effective weight loss medications (e.g., semaglutide, tirzepatide) were not available.
No takes yet. Share an insight, caveat, or question.
Dutta et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: